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Summary
Background: Crohn's disease (CD) is a predisposing factor for bone loss and mus-
cle dysfunction, which could lead to osteoporotic fractures and physical disability, 
respectively.
Aim: To assess the effect of 6 months of combined impact and resistance training on 
bone mineral density (BMD) and muscle function in adults with CD.
Methods: In this randomised controlled trial, 47 adults with stable CD were assigned 
to exercise (n = 23) or control (n = 24) groups and followed up for 6 months. The exer-
cise group received usual care plus a 6-month combined impact and resistance train-
ing programme, involving three, 60-minute sessions per week and a gradual tapering 
of supervision to self-management. The control group received usual care alone. The 
primary outcomes were BMD (via dual energy X-ray absorptiometry) and muscle 
function (measures of upper and lower limb strength and endurance) at 6 months.
Results: At 6 months, BMD values were superior in the exercise group with statistical 
significance at lumbar spine (adjusted mean difference 0.036 g/cm2, 95% CI 0.024-
0.048; P < 0.001), but not at femoral neck (0.018 g/cm2, 0.001-0.035; P = 0.059) or 
greater trochanter (0.013 g/cm2, −0.019 to 0.045; P = 0.415) after correcting for mul-
tiple outcomes. The exercise group also had superior values for all muscle function 
outcomes (P < 0.001; unadjusted mean differences ranging 22.6‒48.2%), and lower 
fatigue severity (P = 0.005). Three exercise-related adverse events were recorded: 
two instances of light-headedness and one of nausea.
Conclusions: The intervention improved BMD and muscle function in adults with CD 
and appears as a suitable model of exercise for reducing future risk of osteoporotic 
fractures and disability.
Trial registration: ISRCTN11470370.
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1  | INTRODUC TION
People with Crohn's disease (CD) have an increased risk of osteoporo-
sis and osteoporotic fractures compared with the general population.1 
Factors contributing to bone loss in CD include chronic inflammation, 
reduced vitamin and mineral absorption, extensive small-bowel disease 
or resection, corticosteroid use, older age, physical inactivity, smoking 
and nutritional deficiencies.2 Bone mineral density (BMD) is one of the 
most important determinants of fracture risk, accounting for 60%-70% 
of the variance in bone strength.3 A 2016 Guideline/Consensus paper 
from the European Crohn's and Colitis Organisation (ECCO) stated that 
weight-bearing exercise, stopping smoking and maintaining adequate 
dietary calcium (1 g/d) may help to prevent bone loss in inflammatory 
bowel disease;4 however, few prospective trials of preventative inter-
ventions have been conducted in this increased-risk group.
Physical activity and exercise are important determinants of 
bone health.5 Gravity-derived impact loads and muscle forces 
during exercise produce strain within the axial skeleton, which is 
osteogenic, stimulating bone formation.6 Observational studies and 
randomised controlled trials (RCTs) indicate that physical activity 
and exercise can have beneficial effects on bone mass and strength 
across the age spectrum, thus reducing the risk of fractures.5 Load 
intensity is one of the most important training variables, with guide-
lines and evidence syntheses indicating that adults should undertake 
a combination of impact activities (eg jumping) and high-intensity 
resistance training to optimise bone health.7-9 Resistance training 
can also improve muscle mass and function,8 which may be of im-
portance in CD where low muscle mass and strength is common and 
predictive of osteopenia/osteoporosis.10,11
Empirical evidence on the effects of exercise in CD is sparse, with 
only a handful of intervention studies, all of which have focused on 
modes of exercise that are sub-optimal for improving bone health (eg 
walking, cycling, yoga).12 Only one RCT has investigated the effect of 
exercise on BMD, but the intervention was a low-impact resistance 
training, ie not a specific bone-loading programme.13 To address this 
evidence gap, we conducted an RCT called PROTECT (PROgressive 
resistance Training Exercise and Crohn's disease Trial), which aimed 
to evaluate the effects of a 6-month combined impact and resistance 
training programme on BMD and muscle function in adults with CD. 
The programme was designed to be practical to deliver by including a 
gradual tapering of supervision to self-management. Secondary aims 
were to explore the safety of the exercise programme and its effects 
on other health markers (eg fatigue, health-related quality of life), 
and to evaluate differences in BMD and muscle function between 
patients and matched healthy controls.
2  | METHODS
2.1 | Study design
PROTECT was a two-arm, randomised, parallel-group and assessor-
blind trial. Participants were randomised 1:1 to receive usual care plus 
a 6-month impact and resistance training programme (intervention) or 
usual care only (control). Study assessments were conducted at baseline 
and at 3 and 6 months after randomisation. Recruitment was from a large 
Hospital Trust in Northern England: Newcastle upon Tyne Hospitals NHS 
Foundation Trust. The exercise and assessment sessions were delivered 
in the exercise science facilities of Northumbria University. The trial was 
prospectively registered with the International Standard Randomised 
Controlled Trial Number registry, number ISRCTN11470370. Ethics ap-
proval was granted by the North East - Tyne & Wear South Research 
Ethics Committee (reference 17/NE/0308).
2.2 | Participants
We included male and female patients aged 16 years or older with 
a clinical diagnosis of CD. Patients had to have a stool calprotec-
tin of <250 μg/g, stable medication (>4 weeks), and quiescent or 
mildly-active disease, as indicated by a Crohn's Disease Activity 
Index (CDAI) of <150 or 150-219, respectively. Exclusion criteria 
were contraindication to exercise testing or training,14 pregnant, 
planned pregnancy or major surgery within the first 6 months after 
randomisation, and current participation in 2 or more sessions per 
week of resistance exercise (self-reported) or another clinical trial 
where concurrent participation was deemed inappropriate.
Recruitment methods included liaisons with members of the direct 
care team during routine hospital appointments, postal invitations to 
patients who had previously consented to be contacted about future 
studies, and advertisements in hospital clinics and on social media. All 
participants provided written informed consent before enrolment.
2.3 | Randomisation and masking
Participants were randomly assigned 1:1 to one of the two trial 
arms using a computer-generated randomisation schedule stratified 
by gender and baseline disease status (quiescent [CDAI < 150] or 
mildly-active [CDAI 150–219]). The randomisation process was man-
aged by an investigator at Northumbria University (GT) who was not 
involved in recruitment, intervention delivery or data collection. A 
researcher (KJ) emailed this investigator for notification of group al-
location once the participant had consented and completed base-
line assessments. Following notification, the researcher contacted 
the participant to inform them of their allocation. Due to the nature 
of the intervention, participants and intervention facilitators were 
not masked to group allocation. Outcome assessors were masked to 
group allocation, and participants were asked to not disclose their 
allocation. This instruction was adhered to by all participants.
2.4 | Procedures
Both groups received usual care, which comprised evidence-based 
medical treatment optimisation. Participants allocated to the control 
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group did not receive any supervised exercise or exercise advice 
during the trial; however, following their final assessment they were 
offered a telephone-based consultation with a researcher who dis-
cussed their individual facilitators/barriers to exercise, and provided 
general advice on incorporating exercise into their lifestyle.
Participants allocated to the exercise group were encouraged 
to complete three, 60-minute exercise sessions on nonconsecutive 
days each week for 26 consecutive weeks, commencing the week 
following their group allocation. Twelve sessions were supervised 
and 66 were unsupervised, with a gradual tapering of supervision 
to self-management as follows: two supervised sessions per week 
in weeks 1 and 2; one supervised session per week in weeks 3 and 
4; one supervised session every fortnight in weeks 5/6 and 7/8; one 
supervised session every month from week 9 onwards. The super-
vised sessions aimed to motivate participants to exercise regularly 
and teach them how to exercise correctly.
Each session involved a warm-up, a main conditioning phase 
and a cool-down. The warm-up lasted approximately 5 minutes 
and included several pulse-raising exercises (eg marching on the 
spot, squat and punch) and dynamic stretches (eg big arm circles, 
forward and backward leg swings). The main conditioning phase 
lasted approximately 50 minutes and involved a combination of 
impact and high-effort resistance exercises to maximise improve-
ments in BMD and muscle function.7-9 The impact exercises in-
cluded rope skipping (up to 5 minutes) and several multi-directional 
jumps (eg squat jump, broad jump, scissor jump; 2-3 sets of 10-15 
repetitions for five different jumps). The resistance exercises tar-
geted the major muscle groups of the upper-body, lower-body and 
mid-section (eg squat, lunge, press-up, reverse fly, lateral raise, 
bicep curl, triceps extension, bridge; 2-3 sets of 10-15 repetitions 
for 8-10 exercises) with resistance provided using the participant's 
own body weight and TheraBand® elastic bands. The intended in-
tensity for each set was moderate-to-hard, which was self-rated 
using the Resistance Intensity Scale for Exercise.15 The cool-down 
lasted approximately 5 minutes and included static stretches for 
the major muscle groups.
Each exercise participant was given four TheraBand elastic bands 
and a skipping rope to keep. They also received an exercise booklet 
(see Supporting Information) that included information about how 
to perform and progress the exercises, tables for self-monitoring of 
adherence, information about TheraBand care and travelling to the 
University, and contact details of the research team. Participants 
were free to contact the intervention facilitator (KJ) by telephone or 
email at any time with questions.
We had planned to use a telehealth app (Florence; www.getfl 
orence.co.uk/) to send the exercise participants regular motivational 
messages to support exercise adherence, but this was unavailable 
during the period of intervention delivery. The intervention facilita-
tor did however contact these participants every 4 weeks to provide 
motivation and support.
Face-to-face assessment visits were conducted before (base-
line), and 3 and 6 months after group allocation. Demographic and 
clinical characteristics were assessed at baseline only. The following 
outcomes were assessed at baseline and both follow-up time-points: 
muscle function, body mass, stature, resting blood pressure and 
heart rate, health-related quality of life, fatigue, physical activity, 
and medications. BMD was assessed at baseline and 6 months only. 
Adverse events and exercise enjoyment were assessed at the two 
follow-up time-points. The acceptability of the intervention was also 
assessed using participant feedback via telephone interviews con-
ducted after the 6-month assessments.
With local institutional approval, 33 healthy adults were also re-
cruited from the local community to allow a case-control compari-
son of BMD, muscle function and quality of life outcomes using the 
trial participants’ baseline data. Participants were matched for age 
(±5 years), gender, physical activity status, body mass index category 
and ethnicity. Healthy control participants completed the assess-
ments twice, one week apart, to allow test-retest reliability statistics 
(two-way random effects intra-class correlation coefficient, ICC) to 
be calculated. ICC values of between 0.75 and 0.90 and greater than 
0.90 were considered indicative of good and excellent reliability, 
respectively.
2.5 | Outcomes
The primary outcomes were BMD and muscle function at 6 months. 
BMD (in g/cm2) was assessed at the hip (left femoral neck and 
greater trochanter; both ICC = 0.999) and lumbar spine (L2-L4; 
ICC = 0.998) using dual energy X-ray absorptiometry (Horizon DXA 
System, Hologic, UK). Muscle function was assessed using sev-
eral measures of upper-body and lower-body strength and endur-
ance. Grip strength (in kg) of the nondominant hand was assessed 
as the best of three attempts using a calibrated Jamar® hydraulic 
hand dynamometer (ICC = 0.992). Lower-body muscular endur-
ance was assessed using a chair stand test,16 in which participants 
complete as many sit-to-stand repetitions as they can in 30 seconds 
(ICC = 0.881). Upper-body muscular endurance was assessed using 
an arm curl test,16 in which participants complete as many full-range 
curls of their nondominant arm as they can in 30 seconds while hold-
ing a dumbbell (5 lb for women, 8 lb for men; ICC = 0.875). Isokinetic 
strength of knee extensors and elbow flexors was assessed as peak 
torque (in Nm) measured during maximal voluntary actions at two 
angular velocities (3-5 repetitions at 60 and 180 °/s for knee exten-
sion, 3-5 repetitions at 60 and 120 °/s for elbow flexion) on an isoki-
netic dynamometer (System 4 Pro, Biodex, UK). Peak torque values 
from both limbs were averaged for use in the analysis (ICC = 0.931 
to 0.991).
Resting blood pressure and heart rate were assessed using an au-
tomated monitor (V100 Dinamap Vital Signs Monitor, GE Carescape, 
UK). Disease-specific health-related quality of life was assessed 
using the total score on the long version of the Inflammatory Bowel 
Disease Quality of Life Questionnaire (IBDQ).17 Generic health-re-
lated quality of life was assessed using the EQ-5D-5L utility index.18 
Fatigue was assessed using the Fatigue Assessment Scale from 
the IBD Fatigue (IBD-F) Scale.19 Physical activity was assessed as 
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minutes per week of physical activity using the Scottish Physical 
Activity Questionnaire.20 Exercise enjoyment was assessed using 
the total and sub-scale scores on the Physical Activity Enjoyment 
Scale.21 We documented all serious adverse events, and all nonse-
rious adverse events that were either deemed to be related to par-
ticipation in the research or resulted in withdrawal from the exercise 
programme or study. An event was classed as serious if it met any 
of the following criteria: fatal; life threatening (ie event in which pa-
tient is at risk of death at the time of the event occurring); requiring 
unplanned or prolonged hospitalisation; resulting in persistent or 
significant disability or incapacity; or resulting in a congenital ab-
normality or birth defect. Nonserious adverse events were defined 
as any untoward medical occurrence that did not fulfil any of the 
serious adverse event criteria.
2.6 | Statistical considerations
We used the distribution-based approach for the sample size calcula-
tion because a minimum clinically important difference has not been 
established for BMD in adults with CD. A target difference of 0.4 SD 
(ie a small-to-moderate effect) was selected because this effect size 
was reported for femoral neck BMD in a meta-analysis of combined 
impact and resistance training programmes in post-menopausal 
women.9 Using the sample size calculation methods of Borm et al,22 
and assuming 80% power, a two-sided α level of 0.05, and a pre-post 
correlation between of r = 0.9, we required 38 participants in total. 
Allowing for 20% loss to follow-up at 6 months, we calculated that 
50 participants were needed to be recruited and randomised.
We used descriptive statistics to show the baseline characteris-
tics of the participants who were enrolled, by treatment group. The 
effect of the intervention was evaluated using separate analysis of 
covariance models for the 3- and 6-month outcomes. The outcome 
at 3 or 6 months was the dependent variable and group (interven-
tion, control) was the independent variable. The baseline value of 
the outcome, gender and disease activity status were included as 
covariates.
The primary analysis used a modified intention-to-treat 
population that included all randomised participants for whom 
treatment was allocated as per the randomised list regardless of 
circumstances after randomisation and who had both baseline and 
follow-up outcome data (ie complete-case analysis). Best-case and 
worst-case sensitivity analyses were also done to explore the im-
pact of missing data, using the group mean plus 1 SD of the group 
mean as a ‘beneficial outcome’ and the group mean minus 1 SD 
of the group mean as a ‘harmful outcome’.23 We report adjusted 
and unadjusted means for each group and the adjusted mean dif-
ference (with 95% CI and p value) between treatment groups at 3 
and 6 months. All statistical tests were two-sided at the 5% sig-
nificance level. In the primary analysis, p-values were corrected 
for multiple testing using the Benjamini-Hochberg procedure.24All 
analyses were performed using IBM SPSS Statistics (version 24, 
IBM Corporation, UK).
3  | RESULTS
Between February 20, 2018 and March 14, 2019, we screened 76 
individuals, of whom 47 were recruited and randomly assigned to 
the exercise or control groups (Figure 1). Forty-three (91%) partici-
pants completed the trial, achieving our target sample size. Table 1 
shows the participant characteristics at baseline. Thirty-two (68%) 
participants were female and the mean age was 49.3 years (SD 13.0). 
All participants were of white ethnicity, none were current smok-
ers, and most had quiescent disease (66%) and were in paid employ-
ment (55%). The median time since diagnosis was 216 months (IQR 
60-388). Based on the baseline BMD measurements, 12 (25%) par-
ticipants had evidence of osteopenia or osteoporosis at the lumbar 
spine and 20 (43%) at the left hip. The most common medications 
used for CD were immunosuppressants (43%) and biologics (40%), 
and no participants were taking corticosteroids. Twenty-seven 
(58%) participants had received one or two prior resections for CD, 
whereas seven (15%) had received three or more. Seven (15%) par-
ticipants had a stoma.
Of the 1,716 exercise sessions that were prescribed in total, 
1,057 (62%) were completed (214/264 [81%] supervised, 843/1,452 
[58%] unsupervised). The median (IQR) number of exercise sessions 
completed by each participant was 50 (36-59) of a possible 78 (10/12 
[8-12] supervised, 39/66 [24-48] unsupervised). This corresponds to 
an average of 2 sessions each week, which is consistent with physical 
activity guidelines for the general adult population.25 The mean (SD) 
total PACES enjoyment scores at 3 and 6 months out of a possible 
126 were 104 (13) and 104 (15), respectively, demonstrating a high 
level of enjoyment (see Supporting Information Figures 1 and 2 for 
PACES sub-item data). The most commonly cited reasons for ses-
sions being missed were work-related tiredness (46 sessions), holi-
day (30 sessions) and work commitments (26 sessions).
Twenty-one exercise participants completed a telephone inter-
view after the 6-month follow-up. All interviewees provided positive 
feedback and said that they would recommend the programme to 
other people with CD. Most/all of the participants expressed that 
the exercise intervention had an appropriate frequency of sessions 
(n = 19), duration of sessions (n = 20), intensity of training (n = 20), 
mode of training (n = 21), and overall programme duration (n = 19). 
Two participants thought that thrice weekly was too often to fit in 
with their lifestyle, one thought that 60-minute sessions were too 
long, one thought that the sessions were too hard for their level of 
fitness, and two thought that the programme duration should be 
greater than 6 months. Table 2 shows summary statistics for primary 
and secondary outcome measures at each assessment time-point. 
Figure 2 shows 6-month percentage change scores in primary out-
come measures. Tables 3 and 4 show adjusted means and group dif-
ferences for primary and secondary outcome measures, respectively. 
Forty-three (91.5%) participants (n = 22 exercise group, n = 21 con-
trol group) provided complete outcome datasets at 3 and 6 months.
In the trial, at 6 months, the BMD values for the exercise group 
were superior to those for the control group with statistical signifi-
cance at lumbar spine (adjusted mean difference 0.036 g/cm2, 95% 
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CI 0.024-0.048; P < 0.001), but not at femoral neck (adjusted mean 
difference 0.018 g/cm2, 95% CI 0.001-0.035; P = 0.059) or greater 
trochanter (adjusted mean difference 0.013 g/cm2, 95% CI −0.019-
0.045; P = 0.415) after correcting for multiple outcomes. When 
expressed as a percentage change from baseline, unadjusted mean 
differences were as follows: lumbar spine 3.8% (95% CI 2.6-5.1, 
P < 0.001), femoral neck 2.3% (95% CI 0.4-4.1, P = 0.018) and greater 
trochanter 1.4% (95% CI −2.2 to 5.1, P = 0.426). Post-hoc exploratory 
analyses revealed a moderately-strong association between the num-
ber of exercise sessions completed and the 6-month change score 
for lumber spine BMD (r = 0.563, P = 0.006) and femoral neck BMD 
(r = 0.453, P = 0.034), but not for greater trochanter BMD (r = 0.090, 
P = 0.691). All muscle function outcomes were also superior in the ex-
ercise group at 6 months (Table 3; unadjusted mean differences rang-
ing from 22.6% to 48.2%). For example, adjusted mean differences 
were 8.3 kg for grip strength (95% CI 6.2 to 10.5; P < 0.001), four 
repetitions for the chair stand test (95% CI 3-6; P < 0.001) and seven 
repetitions for the bicep curl test (95% CI 5-8; P < 0.001).
At 3 months, all muscle function outcomes were superior in the 
exercise group (Table 4). For example, adjusted mean differences 
were 12.9 Nm for isokinetic knee extension at 60°/s (95% CI 2.5-
23.3; P = 0.016) and 5.2 Nm for isokinetic elbow flexion at 60°/s 
(95% CI 2.8-7.6; P < 0.001). There were no between-group dif-
ferences at either time-point for systolic blood pressure, diastolic 
blood pressure or physical activity (Table 4). Resting heart rate 
values were lower in the exercise group at both 3 and 6 months 
(adjusted mean differences −5 [95% CI −10 to 0] and −6 beats/
min [95% CI −12 to −1], respectively; both P = 0.032). Measuring 
disease-specific health-related quality of life with the IBDQ total 
score, we saw evidence of improvement in the exercise group at 
3 months (adjusted mean difference 17, 95% CI 7-26; P = 0.001), 
but this difference was not evident at 6 months (adjusted mean 
difference 6, 95% CI −3 to 15; P = 0.175). Generic health-related 
quality of life, assessed using the EQ-5D utility index was superior 
in the exercise group at both 3 and 6 months (adjusted mean dif-
ferences 0.117 [95% CI 0.023-0.211, P = 0.016] and 0.109 [95% CI 
0.038-0.181, P = 0.004], respectively). Fatigue (IBD-F score) was 
lower in the exercise group at 6 months (adjusted mean difference 
−2, 95% CI −4 to −1; P = 0.005), but not 3 months (adjusted mean 
difference −1, 95% CI −3 to 1; P = 0.249).
F I G U R E  1   Trial profile






1 withdrew form study 3 withdrew form study
1 disease flare
1 allergic reaction to Infliximab
1 uncontactable
1 family commitments
22 followed up at







21 followed up at
3 and 6 months
24 assigned to
control group
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Three exercise-related adverse events were recorded: two in-
stances of light-headedness and one of nausea. Other adverse events, 
which were recorded but deemed unrelated to the research, included 
a transient ischaemic attack (exercise group), a disease flare-up (control 
group), and an allergic reaction to Infliximab (control group). The latter 
two resulted in withdrawal from the study. At 6 months, the median 
(IQR) scores for CDAI and faecal calprotectin were 76 (31-104) and 34 
(26-97), respectively, for the exercise group and 116 (62-165) and 141 
(59-245), respectively, for the control group. One control participant 
experienced disease relapse between baseline and 6 months, as de-
fined by an increase in CDAI of ≥100 points to a score ≥150.
Data for the best-case and worst-case sensitivity analyses are 
shown in tables 1 and 2 of the Supporting Information file, respec-
tively. The effect sizes and significance values were not substantially 
altered for any of the muscle function outcomes. The BMD outcomes 
appeared more sensitive to missing data; for example, effect sizes 
for lumbar spine and femoral neck BMD at 6 months were increased 
in the best-case sensitivity analysis (adjusted mean differences 
Exercise (n = 23) Control (n = 24) Total (n = 47)
Age (years) 46.1 (11.9) 52.3 (13.6) 49.3 (13.0)
Male gender 7 (30) 8 (33) 15 (32)
Body mass index (kg/m2) 26.0 (3.1) 27.1 (5.1) 26.6 (4.3)
Employment status
Working full- or part-time 11 (48) 15 (62.5) 26 (55)
Student 3 (13) 3 (12.5) 6 (13)
Other 9 (39) 6 (25) 15 (32)
CD duration (months) 216 (60-388) 198 (61-374) 216 (60-388)
CD location
Ileum 5 (22) 10 (42) 15 (32)
Colon 8 (35) 4 (17) 12 (26)
Ileum-colon 9 (39) 9 (37) 18 (38)




14 (61) 17 (71) 31 (66)
Stricturing 5 (22) 6 (25) 11 (23)
Penetrating 4 (17) 1 (4) 5 (11)
CD activity status
Quiescent 15 (65) 16 (67) 31 (66)
Mildly active 8 (35) 8 (33) 16 (34)
CDAI 98 (50-151) 112 (78-188) 101 (65-159)
Medication for CD
Immunosuppressants 13 (57) 7 (29) 20 (43)
Biologics 7 (30) 12 (50) 19 (40)
Number of resections
0 6 (26) 7 (29) 13 (28)
1 10 (43) 11 (46) 21 (45)
2 3 (13) 3 (12.5) 6 (13)
3 or more 4 (17) 3 (12.5) 7 (15)
Stoma 5 (22) 2 (8) 7 (15)
Serum C-reactive protein
<5 mg/L 22 (96) 21 (87.5) 43 (91)
≥5 mg/L 1 (4) 3 (12.5) 4 (9)
Faecal calprotectin (µg/g) 36 (26-52) 47 (26-139) 41 (26-93)
Note: Data are n (%), mean (SD), and median (IQR).
Abbreviations: CD, Crohn's disease; CDAI, Crohn's Disease Activity Index; GI, gastrointestinal.
TA B L E  1   Baseline characteristics
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0.085 g/cm2 [95% CI 0.027-0.124, P = 0.005] and 0.052 g/cm2 [95% 
CI 0.010-0.095, P = 0.017], respectively), and reduced in the worst-
case sensitivity analysis (adjusted mean differences 0.014 g/cm2 
[95% CI −0.030 to 0.059, P = 0.521] and 0.006 g/cm2 [95% CI −0.026 
to 0.037, P = 0.704], respectively).
Data for the case-control comparisons are presented in Tables 
3 And 4 of the Supporting Information file. The trial participants 
(n = 33) and healthy controls (n = 33) were well-matched for age, 
gender, ethnicity, body mass index, smoking status, and blood pres-
sure; however, resting heart rate was higher in trial participants (79 
[9] vs 70 [13] beats/min; P = 0.002). Compared with the healthy con-
trols, trial participants had lower BMD values at the lumbar spine 
(0.957 [0.116] vs 1.020 [0.143] g/cm2) and femoral neck (0.734 
[0.122] vs 0.796 [0.160] g/cm2). The mean difference adjusting for 
age, gender, smoking status and physical activity was 0.066 g/cm2 
(95% CI 0.003 to 0.129; P = 0.040) and 0.063 g/cm2 (95% CI 0.001-
0.125; P = 0.045), respectively. The between-group difference in 
greater trochanter BMD was small and nonsignificant (Supporting 
Information, table 4). Trial participants had inferior scores for all 
of the muscle functions outcomes except isokinetic elbow flex-
ion (Supporting Information, table 4). For example, grip strength 
was 32.7 kg (11.3) in trial participants and 35.7 kg (11.7) in healthy 
control (adjusted mean difference 3.3 kg, 95% CI 0.2-6.3; P = 0.037). 
The EQ5D utility index scores also indicated that, at baseline, trial 
participants had lower health-related quality of life (adjusted mean 
difference 0.098, 95% CI 0.032-0.165; P = 0.004).
4  | DISCUSSION
In this RCT involving adults with quiescent or mildly-active CD, the 
offer of a combined impact and resistance exercise programme with 
gradual tapering of supervision to independent practice improved 
BMD and muscle function at 6-month follow-up compared with 
usual care control. The intervention was also associated with im-
provements in generic health-related quality of life and fatigue at 
6 months. The exercise programme required minimal direct supervi-
sion and appeared acceptable and safe for participants.
Consensus guidelines on the management of inflammatory 
bowel disease state that weight-bearing and resistive exercises 
should be promoted to help prevent bone loss.4,26 However, specific 
exercise prescriptions are not provided, and the recommendation is 
based largely on research in the general population.27 Findings from 
the general population are unlikely to be generalisable to people 
F I G U R E  2   Six-month mean change 
(±SE) in (A) bone and (B) muscle function 
outcomes for the exercise and control 
groups. ACT, arm curl test; BMD, bone 
mineral density; CST, chair stand test; 
EF60, elbow flexion 60°/s; EF120, elbow 
flexion 120°/s; FN, femoral neck; GS, 
grip strength; GT, greater trochanter; 
KE60, knee extension 60°/s; KE180, knee 
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with CD because this condition can pose specific barriers to par-
ticipation in exercise (e.g. fatigue, abdominal pain, faecal urgency, 
perianal symptoms28) and can have disease-specific effects that limit 
improvements in BMD and muscle function (eg chronic inflamma-
tion, reduced vitamin and mineral absorption).2 PROTECT there-
fore provides novel data on the feasibility and efficacy of a specific 
bone-loading exercise programme in this population, which may help 
guide clinical practice.
Our findings suggest that the exercise programme was accept-
able and safe, and that it can improve BMD to a similar extent as to 
that seen previously in post-menopausal women. For example, the 
mean treatment effects of 3.8% and 2.3% at the lumbar spine and 
femoral neck, respectively, are similar to those reported in the re-
cent LIFTMOR trial (4.1% and 2.3%, respectively), which tested an 
8-month combined impact and resistance training programme (two 
supervised 30-minute sessions per of week),29 and the findings of 
an earlier meta-analysis from 2015 (1.8% [10 RCTs, n = 1147] and 
2.4% [7 RCTs, n = 940], respectively).9 Such improvements may be 
considered as clinically important because a recent meta-regression 
analysis indicated that a 2% improvement in lumbar spine or femoral 
neck BMD was associated with a 28% reduction in vertebral frac-
ture risk, and a 15%-22% reduction in hip fracture risk.30 However, 
it is important to acknowledge that training effects may disappear 
if training is discontinued,31 so exercise training would need to be 
maintained in the long-term to prevent osteoporosis and osteopo-
rotic fractures in later life.
Skeletal muscle weakness is a peripheral manifestation of CD,10,11 
and a risk factor for falls and fall-related fractures,32 mobility dis-
ability33 and major post-operative complications.34 Consequently, 
a reduction in the risk of these adverse outcomes may be achieved 
through exercise programmes that improve muscle function. We have 
shown that combined impact and resistance training enhances a broad 
range of muscle function outcomes, including measures of upper- and 
lower-body muscular strength and endurance, in adults with CD. 
Therefore, the exercise programme seems to be suitable for improving 
BMD and muscle function simultaneously. It is also notable that the 
deficits in muscle function that were observed relative to healthy con-
trols at baseline were no longer apparent at the 6-month follow-up.
Fatigue is a common and burdensome symptom in people with 
CD, even for those in clinical remission.35 It can have a negative 
impact on personal and social life, on work and employment, and 
the ability to think clearly.36 At present, there is no consensus on 
how to manage CD-related fatigue, which may be explained by 
its varied and incompletely-understood aetiology, and a lack of 
TA B L E  2   Summary of outcomes
Exercise group Control group
Baseline (n = 23) 3 months (n = 22) 6 months (n = 22) Baseline (n = 24) 3 months (n = 21) 6 months (n = 21)
Bone mineral density (g/cm2)
Lumbar spine 1.068 (0.156) - 1.111 (0.151) 1.037 (0.219) - 1.032 (0.236)
Greater trochanter 0.728 (0.113) - 0.737 (0.112) 0.678 (0.102) - 0.676 (0.108)
Femoral neck 0.812 (0.142) - 0.845 (0.154) 0.753 (0.129) - 0.759 (0.129)
Grip strength (kg) 36.4 (13.1) 39.4 (12.1) 42.4 (12.6) 32.2 (12.2) 31.8 (10.8) 31.0 (11.6)
Chair stand test (repetitions) 14 (3) 17 (3) 19 (3) 13 (3) 14 (3) 14 (3)
Arm curl test (repetitions) 16 (3) 20 (3) 24 (3) 16 (4) 17 (4) 17 (3)
Isokinetic strength (Nm)
Knee extension 60°/s 82.5 (44.0) 98.2 (47.5) 104.3 (52.6) 74.9 (36.2) 77.9 (38.4) 74.4 (34.7)
Knee extension 180°/s 51.9 (32.7) 62.7 (34.6) 67.8 (34.2) 47.6 (23.1) 47.8 (26.4) 47.0 (34.2)
Elbow flexion 60°/s 30.2 (16.0) 34.1 (16.4) 36.5 (16.5) 26.4 (10.9) 25.3 (11.3) 26.2 (11.6)
Elbow flexion 120°/s 25.5 (12.1) 29.6 (14.9) 30.6 (14.0) 23.6 (10.0) 22.0 (10.1) 22.7 (11.2)
Systolic blood pressure 
(mmHg)
136 (21) 126 (15) 129 (14) 132 (20) 131 (16) 127 (18)
Diastolic blood pressure 
(mmHg)
81 (13) 75 (11) 76 (9) 75 (9) 76 (7) 77 (10)
Resting heart rate  
(beats/min)
79 (10) 73 (8) 75 (11) 80 (11) 79 (12) 82 (11)
IBDQ total score (32-224) 183 (23) 191 (20) 187 (23) 166 (25) 162 (26) 166 (29)
EQ-5D utility index  
(−0.285 to 1)
0.856 (0.123) 0.872 (0.115) 0.885 (0.128) 0.810 (0.113) 0.729 (0.189) 0.749 (0.137)
Fatigue score (0-20) 6 (4) 6 (4) 5 (3) 9 (4) 9 (4) 10 (5)
Physical activity (min/week) 1498 (1049) 1544 (1057) 1456 (924) 794 (782) 728 (621) 1032 (917)
Note: Data are mean (SD).
Abbreviations: IBDQ, Inflammatory Bowel Disease Questionnaire.
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intervention-based research on this topic.35 Observational studies 
have revealed fatigue to be negatively associated with physical ac-
tivity, cardiorespiratory fitness and muscle strength;28,37 therefore, 
highlighting exercise as a candidate intervention. The current study 
provides support for a beneficial role of exercise by demonstrating 
that fatigue severity (IBD-F score) was an average of 2 points lower 
in the exercise group at 6 months (95% CI −4 to −1; P = 0.005). Only 
two other trials have examined the effect of exercise on IBD-related 
fatigue, with inclusive findings. McNelly et al. conducted a 2 × 2 fac-
torial trial of self-managed exercise and omega-3 supplementation 
in 60 adults with inactive IBD.38 The exercise intervention involved 
individualised advice to increase physical activity levels by at least 
30%, supported goal setting and diary-based monitoring of exercise 
behaviour. At the 12-week follow-up, fatigue severity, as measured 
by the IBD-F scale, was lower in participants receiving the exercise 
intervention vs placebo control (mean difference −2, 95% CI −3.8 
to −0.2; P = 0.03). However, there was no significant difference in 
fatigue when measured by the FACIT-F score (P = 0.38). A recent 
three-arm RCT that explored the feasibility of high-intensity interval 
training and moderate-intensity continuous training (both on a cycle 
ergometer) in adults with CD (n = 36) also had unclear effects on fa-
tigue (IBD-F score), although the study was underpowered to assess 
efficacy.39 Larger studies investigating the effect of exercise training 
on IBD-related fatigue are warranted.
Although not a primary focus of this study, we also observed that 
the exercise programme had a beneficial effect on generic health-re-
lated quality of life assessed using the EQ-5D utility index (Table 4). 
Inspection of the summary data in Table 2 indicated that the be-
tween-group differences at follow-up were as much explained by a 
deterioration in quality of life in the control group as an improvement 
in the intervention group. This was an unexpected finding because 
the control group had unrestricted access to usual care and did not 
receive any specific advice against exercising. It also stands in con-
trast with both our IBDQ data (Table 2) and EQ-5D data from previ-
ous studies that have used a similar study design.39-41 Nevertheless, 
we cannot totally rule out the potential harm of randomising patients 
who may be interested in an exercise-based intervention to a com-
parator group that does not receive exercise. This point is worthy 
of consideration by researchers designing future trials in this area.
Strengths of this study include the combination of RCT and 
case-control components, a trial population that appears repre-
sentative of the wider clinical population,42 the use of objective 
and reliable measures to assess BMD and muscle function, and the 
intervention design, which included an evidence-based exercise 
prescription for improving bone health and a practical mode of de-
livery to facilitate translation of the findings into routine practice. 
However, a limitation was the sole use of BMD to measure changes 
in bone strength. Although BMD has been shown to account for 
Exercise group Control group Difference p value
Bone mineral density (g/cm2)
Lumbar 
spine



















18 (17-20) 14 (13-16) 4 (3-6) <0.001
Arm curl test 
(repetitions)

















29.8 (27.8-31.9) 23.6 (21.4-25.7) 6.3 (3.3-9.3) <0.001
Note: Data are mean and adjusted mean difference with 95% CIs in parentheses.
TA B L E  3   Adjusted means and group 
differences for primary outcomes at 
6 months
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approximately 60%-70% of the variation in bone strength, it does 
not account for other aspects of bone quality such as microar-
chitecture, the amount of fatigue damage it has sustained, and 
changes in its bulk material properties. Thus, the potential ben-
efits of exercise on bone strength, when limited to BMD, may be 
underestimated. Another limitation was that the intervention did 
not involve any impact exercises for the upper-limbs (eg punching), 
thus future research should include a focus on upper-body bone 
health.
In summary, a 6-month combined impact and resistance training 
programme improved BMD and muscle function in adults with CD. 
The intervention appears a suitable model of exercise for reducing 
the future risk of osteoporotic fractures and physical disability in this 
increased-risk population.
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